Cited in:


This article has been cited by:

  1. 1
    S. L. Stramer, R. Y. Dodd, C. Y. Chiu, Advances in testing technology to ensure transfusion safety – NAT and beyond, ISBT Science Series, 2015, 10, S1
  2. 2
    P. Kiely, C. R. Seed, Assessing infectious threats – trick or threat?, ISBT Science Series, 2015, 10, S1
  3. 3
    Giovanni Di Minno, Carlo Federico Perno, Andreas Tiede, David Navarro, Mariana Canaro, Lutz Güertler, James W. Ironside, Current concepts in the prevention of pathogen transmission via blood/plasma-derived products for bleeding disorders, Blood Reviews, 2015,


  4. 4
    M. P. Busch, Testing for HIV – the first three decades, ISBT Science Series, 2015, 10, S1
  5. 5
    S. L. Stramer, Current perspectives in transfusion-transmitted infectious diseases: emerging and re-emerging infections, ISBT Science Series, 2014, 9, 1
  6. 6
    S. Bakkour, D. M. Chafets, L. Wen, P. F. Meer, J. M. Mundt, S. Marschner, R. P. Goodrich, M. P. Busch, T.-H. Lee, Development of a mitochondrial DNA real-time polymerase chain reaction assay for quality control of pathogen reduction with riboflavin and ultraviolet light, Vox Sanguinis, 2014, 107, 4
  7. 7
    D. Teo, Emerging and imported infections in the region – what's bothering us today?, ISBT Science Series, 2014, 9, 1
  8. 8
    M. P. Busch, Infectious risks of blood transfusions: Recent advances in testing technologies and new approaches to surveillance and decision-making, ISBT Science Series, 2014, 9, 1
  9. You have free access to this content9
    E. Berntorp, G. Dolan, C. Hermans, M. Laffan, E. Santagostino, A. Tiede, Pharmacokinetics, phenotype and product choice in haemophilia B: how to strike a balance?, Haemophilia, 2014, 20,
  10. 10
    C. R. Seed, Risk reduction strategies for transfusion-transmissible arboviral infections, ISBT Science Series, 2014, 9, 1